2-pyrrolidone has been researched along with piracetam in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Altomare, C; Carotti, A; Carrupt, PT; Casini, G; Cellamare, S; Ferappi, M; Gaillard, P; Gavuzzo, E; Mazza, F; Testa, B | 1 |
| Ghelardini, C; Gualtieri, F; Guandalini, L; Martelli, C; Martini, E; Scapecchi, S | 1 |
| Bialer, M; Finnell, RH; Isoherranen, N; Merriweather, M; Roeder, M; Schurig, V; Spiegelstein, O; Triplett, AA; Yagen, B; Zhang, J | 1 |
3 other study(ies) available for 2-pyrrolidone and piracetam
| Article | Year |
|---|---|
X-ray crystal structure, partitioning behavior, and molecular modeling study of piracetam-type nootropics: insights into the pharmacophore.
Topics: Chemical Phenomena; Chemistry, Physical; Crystallography, X-Ray; Lipids; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Molecular Structure; Nootropic Agents; Piracetam; Solubility; Stereoisomerism; Structure-Activity Relationship | 1995 |
2-pyrrolidinone moiety is not critical for the cognition-enhancing activity of piracetam-like drugs.
Topics: Animals; Avoidance Learning; Drug Design; Mice; Nootropic Agents; Piracetam; Pyrrolidinones; Structure-Activity Relationship | 2003 |
Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyl-oxo-pyrrolidine acetamide in a mouse model of teratogenicity.
Topics: Animals; Butyrates; Disease Models, Animal; Female; Fetus; Levetiracetam; Mice; Piracetam; Pregnancy; Prenatal Exposure Delayed Effects; Pyrrolidines; Pyrrolidinones; Teratogens | 2003 |